Breaks Categories: News

TuesdayNov 15, 2016 1:05 pm

Viking Therapeutics, Inc. (VKTX) Presents Additional Results of VK2809 for Treatment of High Cholesterol; Shares Higher

Viking Therapeutics (NASDAQ: VKTX) is trading higher after the clinical-stage biopharmaceutical company announced additional data from its previously completed phase 1b clinical trial designed to evaluate the safety and tolerability of VK2809 in subjects with mild hypercholesterolemia, or high cholesterol. As presented in a poster presentation earlier this week at the American Heart Association (AHA) Scientific Sessions 2016 in New Orleans, the new results show VK2809's effect on additional proteins associated with cardiovascular disease. "These data support the promise of thyroid beta-targeted approaches for the treatment of cardiovascular and other metabolic diseases.  We previously reported results showing VK2809's ability to…

Continue Reading

TuesdayNov 15, 2016 11:31 am

Moxian, Inc. (MOXC) Raises $10M in Public Offering, Uplists to NASDAQ

Moxian, Inc. (NASDAQ: MOXC) this morning made its debut on the NASDAQ Capital Market after a successful uplist from the OTCQB. The provider of an innovative offline-to-online (O2O) integrated social media platform also announced the completion of its public offering, for which it expects gross proceeds of about $10 million. To view the full press release, visit: http://nnw.fm/Rq2EN About Moxian, Inc. Moxian (MOXC) engages in the business of providing social marketing and promotion platforms to merchants who desire to promote their businesses through online social media. The company’s products and services aim to enhance the interaction between users and merchant…

Continue Reading

MondayNov 14, 2016 12:06 pm

Celldex Therapeutics (CLDX): CDX-1140 Data Shows Potential; Shares Climb

Shares of Celldex Therapeutics (NASDAQ: CLDX) are higher Monday morning after the company said it presented data on new product candidate CDX-1140, a fully human antibody targeted to CD40 that has demonstrated potent agonist activity. The data were presented over the weekend at the Society for Immunotherapy of Cancer Annual Meeting (SITC). Key findings include: CDX-1140 binds CD40 with high affinity and specificity and does not block CD40 ligand binding CDX-1140 has an unmodified IgG2 backbone and demonstrates potent agonist activity independent of Fc receptor interactions CDX-1140 demonstrates direct anti-tumor activity in immune-deficient mice challenged with human lymphomas Pharmacological activity…

Continue Reading

MondayNov 14, 2016 11:56 am

Acquisition Strategy Sets Medical Transcription Billing Corp. (MTBC) on Pace for Incremental Profits

Recently posting its fourth straight quarter of positive adjusted EBITDA and another quarter of YoY revenue growth, healthcare IT company Medical Transcription Billing, Corp. (NASDAQ: MTBC) (NASDAQ: MTBCP) is demonstrating increased momentum of its aggressive acquisition-based strategy.  The company most recently acquired Texas-based medical billing company MediGain, LLC, including substantially all of its assets and its subsidiary, for $7 million. “In total, the accounts in good standing acquired through this transaction have annual revenues in excess of $10 million … the MediGain acquisition is expected to be accretive to MTBC shareholders in 2017, as incremental profits are expected to greatly…

Continue Reading

FridayNov 11, 2016 1:13 pm

Genocea Biosciences, Inc. (GNCA): ATLAS™ Study Demonstrates Potential for Personalized Cancer Vaccines; Shares Climb

Genocea Biosciences (NASDAQ: GNCA) is trading higher after the developer of cell-directed vaccines and immunotherapies reported data supporting the potential of its proprietary antigen identification screening system, ATLAS™, to identify personalized neoantigens that could guide development of neoantigen vaccines. Conducted in collaboration with Memorial Sloan Kettering Cancer Center (MSK), the study analyzed neoantigens in one non-small cell lung cancer patient successfully treated with pembrolizumab (KEYTRUDA®). Data will be presented at the Society for Immunotherapy of Cancer’s (SITC) 31st Annual Meeting & Associated Programs on November 12, 2016. To view the full press release, visit: http://nnw.fm/op5sS About Genocea Genocea is harnessing…

Continue Reading

WednesdayNov 09, 2016 10:17 am

Bristol-Myers Squibb Company (BMY), Infinity Pharmaceuticals, Inc. (INFI) Team Up to Evaluate Combination in Solid Tumors Study; Shares Jump

Shares of Bristol-Myers Squibb (NYSE: BMY) and Infinity Pharmaceuticals (NASDAQ: INFI) are higher after the companies announced their clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s IPI-549 in patients with advanced solid tumors. The dose-escalation portion exploring IPI-549 as a monotherapy in Infinity’s phase 1 study is continuing, and the first dose-escalation cohort studying IPI-549 in combination with Opdivo, a PD-1 immune checkpoint inhibitor, is scheduled to begin this fall. To view the full press release, visit: http://nnw.fm/V4tfN About Infinity Pharmaceuticals, Inc. Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with…

Continue Reading

TuesdayNov 08, 2016 1:39 pm

Great Basin Scientific, Inc. (GBSN) Finishes Trial for Stool Bacterial Pathogens Panel; Shares Lower

Great Basin Scientific (OTCQB: GBSN) this morning reported the completion of its clinical trial of Stool Bacterial Pathogens Panel, a technology designed to detect Salmonella species, Shigella species, Shiga Toxin-producing E. coli species (stx1 and stx 2, O157), and Camphylobacter species (C. jejuni and C. coli). From here Great Basin intends to pursue 510(k) clearance from the Food and Drug Administration (FDA) as well as CE marking. To view the full press release, visit: http://nnw.fm/t5AgC About Great Basin Scientific Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies.  The Company is dedicated to the development of…

Continue Reading

TuesdayNov 08, 2016 10:50 am

ChromaDex Corp. (CDXC) Shares Tick Higher on $5M Credit Facility

ChromaDex (NASDAQ: CDXC) is trading higher this morning after announcing its $5 million credit facility with Bridge Bank. ChromaDex innovates proprietary health, wellness and nutritional ingredients that create science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products. The company says the credit facility provides the capital needed to expand its proprietary ingredient business. To view the full press release, visit: http://nnw.fm/9joXj About ChromaDex: ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition…

Continue Reading

TuesdayNov 08, 2016 10:47 am

Orexigen Therapeutics, Inc. (OREX) Inks Deal with Valeant Pharmaceuticals to Commercialize Contrave Weight Loss Drug; Shares Soar

Shares of Orexigen Therapeutics (NASDAQ: OREX) jumped more than 27% in morning trade after the company announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., will work with Valeant Pharmaceuticals International, Inc. to commercialize Orexigen’s weight loss drug, Contrave®,  in Australia and New Zealand. Per the agreement, Valeant will be responsible for obtaining regulatory approvals and for all commercialization activities; Orexigen will supply Contrave tablets to Valeant for an agreed transfer price and certain potential sales milestone payments. Orexigen said it expects Valeant to file for regulatory approvals in both countries in the first half of 2017. To view…

Continue Reading

FridayNov 04, 2016 11:16 am

FuelCell Energy, Inc. (FCEL) Installs 5.6MW Power Plant for Pfizer; Shares Climb

Shares of FuelCell Energy (NASDAQ: FCEL) are higher after the company said it has completed the construction and commercial operations of a previously announced 5.6 megawatt fuel cell project on Pfizer, Inc.’s (NYSE: PFE) R&D facility in Groton, Connecticut. The project is part of a 20-year power purchase agreement between a FuelCell subsidiary and Pfizer. To view the full press release, visit:  http://nnw.fm/jAhU4 About FuelCell Energy Direct FuelCell® power plants are generating ultra-clean, efficient and reliable power on three continents, affordably providing continuous distributed power generation to a variety of industries including utilities, commercial and municipal customers.  The Company’s power…

Continue Reading